Turtle Creek Wealth Advisors LLC Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Turtle Creek Wealth Advisors LLC has acquired a new stake in Vertex Pharmaceuticals, purchasing 777 shares valued at approximately $346,000.
• Vertex Pharmaceuticals reported earnings of $4.52 per share for the last quarter, exceeding estimates and achieving revenue of $2.94 billion, a year-over-year increase of 11.3%.
• Analysts have mixed ratings for Vertex Pharmaceuticals, with a current average rating of "Moderate Buy" and a price target averaging $494.38.

Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 777 shares of the pharmaceutical company's stock, valued at approximately $346,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Activest Wealth Management purchased a new stake in shares of Vertex Pharmaceuticals during the 1st quarter valued at $25,000. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 45 shares during the last quarter. Flaharty Asset Management LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 1st quarter valued at $32,000. American National Bank & Trust lifted its holdings in shares of Vertex Pharmaceuticals by 515.4% during the 2nd quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company's stock valued at $36,000 after purchasing an additional 67 shares during the last quarter. Finally, University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Vertex Pharmaceuticals during the 1st quarter valued at $46,000. Hedge funds and other institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $408.61 on Friday. The company has a market capitalization of $104.76 billion, a price-to-earnings ratio of 29.21 and a beta of 0.43. The company's 50 day simple moving average is $394.46 and its 200 day simple moving average is $437.23. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.28. The business had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company's quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

VRTX has been the subject of a number of research analyst reports. Royal Bank Of Canada reduced their target price on Vertex Pharmaceuticals from $430.00 to $405.00 and set a "sector perform" rating for the company in a research note on Tuesday, August 5th. Leerink Partnrs raised shares of Vertex Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, September 25th. Leerink Partners raised shares of Vertex Pharmaceuticals from a "market perform" rating to an "outperform" rating and reduced their price target for the company from $458.00 to $456.00 in a research report on Thursday, September 25th. Evercore ISI reduced their target price on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an "outperform" rating for the company in a report on Thursday, September 11th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Vertex Pharmaceuticals from $517.00 to $530.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have given a Hold rating to the company's stock. According to MarketBeat, Vertex Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $494.38.

Insiders Place Their Bets

In related news, Director Bruce I. Sachs purchased 5,000 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were bought at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the purchase, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. This trade represents a 12.50% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.